Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

191.16 USD -6.55 (-3.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 769,248
Open 197.47
Bid (Size) 172.70 (1)
Ask (Size) 209.47 (1)
Prev. Close 197.71
Today's Range 190.19 - 197.94
52wk Range 119.29 - 212.00
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development... 
From Business Wire News Releases
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2021 on Thursday,... 
From Business Wire News Releases

Performance

YTD
+49.23%
+49.23%
1 Month
-1.39%
-1.39%
3 Month
+4.98%
+4.98%
6 Month
+33.18%
+33.18%
1 Year
+50.73%
+50.73%

More News

Read More
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
From Business Wire News Releases
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
From Business Wire News Releases
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
From Business Wire News Releases
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
From Business Wire News Releases
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
From Business Wire News Releases
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Business Wire News Releases
Notable Monday Option Activity: ALNY, NBIX, DDD
Tags Stocks
From Market News Video
Where Alnylam Pharmaceuticals Stands With Analysts
Tags Analyst Ratings ALNY Benzinga
From Benzinga
3 Top Breakout Stocks to Buy Right Now
Tags NTLA VIR CELH
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.